Dr. Robert Winter
Consultant Respiratory Physician
University College Hospital
Dr. Robert Winter, MD, is a member of the medical staff of Papworth Hospital, the United Kingdom's largest specialty cardiothoracic hospital and the country's main heart and lung transplant center, where the services include cardiology, respiratory medicine, and cardiothoracic surgery. In addition to his position as a consultant respiratory physician at Papworth, which is located in Cambridgeshire, England, Dr. Winter also practices at Squire Cambridge Lea Hospital and is a consultant physician at Addenbrooke's Hospital NHS Trust in Cambridge. He was also appointed medical director of the U.K.'s National Health Service (NHS) East of England division in January 2008.
In addition, Dr. Winter serves as an associate lecturer at the University of Cambridge and is Chairman of the Acute Care Clinical Pathway Group, Chairman of the Emergency Care Steering Group at Addenbrooke's Hospital, Chairman of the East of England Medical Directors' Forum, a member of the Addenbrooke's Charitable Trust (ACT) Grants Committee and Research Advisory Committee, and Chairman of the Professional Advisory Committee.
In practice since 1977, Dr. Winter received his training in general and respiratory medicine at University College Hospital, Royal Brompton Hospital and Hammersmith Hospital, all in London. He currently serves as an examiner for the Royal College of Physicians and has served on the editorial boards of medical journals Medicine and Hospital Medicine. Winter has also been an associate editor for the journal Thorax.
Winter notes that his prime clinical interest is in adult respiratory medicine and he has been an active researcher in this particular field. Currently, Dr. Winter is serving as the primary investigator in a malignant mesothelioma clinical trial entitled "Prospective Randomized Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cyto-reductive Pleurectomy Compared to Talc Pleurodesis in Patients with Suspected or Proven Malignant Mesothelioma." The purpose of this randomized Phase III trial is to study video-assisted surgery to measure its success when compared with talc pleurodesis in treating patients with malignant mesothelioma. Specifically, researchers are attempting to measure the effectiveness of the surgery in regards to the treatment of pleural effusion (fluid build-up) and whether the surgery will cause less damage to normal tissue than the pleurodesis procedure.
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Papworth Hospital NHS Foundation Trust